Table 2 DIC with hematological malignancy: Patients’ characteristics
Background factor | Median (range) or n (%) |
|---|---|
Sex, n (%) | |
 Male | 318 (39.5) |
 Female | 487 (60.5) |
Age, years | 63 (0–92) |
DIC duration before TM-α treatment, days | 0 (−1–31) |
Total dose of TM-α, U/kg | 380 (100.6–549) |
Duration of TM-α | 6 (1–28) |
Prior DIC treatment, n (%) | |
 + | 197 (24.5) |
 - | 608 (75.5) |
Prior heparan sulfate and low molecular weight heparin, n (%) | |
 + | 101 (12.5) |
 - | 70.4 (87.5) |
Prior serine protease inhibitors, n (%) | |
 + | 92 (11.4) |
 - | 713 (88.6) |
Prior AT, n (%) | |
 + | 42 (5.2) |
 - | 763 (94.8) |
Platelet, 104/μL | 3.25 (0.2–51.9) |
PT ratio | 1.26 (0.76–7.55) |
FDP, μg/mL | 48.4 (0.8–1760) |
FBG, mg/dL | 204 (14–966.5) |
AT, % | 86.1 (10.2–150) |
JMHW DIC score | 4 (3–9) |